Apatinib in Neoadjuvant Therapy for Patients With Breast Cancer
Status:
Enrolling by invitation
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
To verify the role of apatinib in neoadjuvant therapy for breast cancer, the investigators
designed a prospective, randomized, parallel-controlled phase II/III trial, to investigate
the efficacy and safety of apatinib combined with TP (paclitaxel + cisplatin) or TP regimen
alone as neoadjuvant therapy for stage II-III breast cancer treatment. 100 cases of eligible
patients were diagnosed by core needle biopsy and immunohistochemistry, with the molecular
subtypes of triple-negative, HER2+ or Luminal B, evaluated by pathological complete remission
(pCR), objective response rate (ORR), adverse events, disease free survival (DFS) and OS,
aiming at providing a new way for neoadjuvant therapy in breast cancer and anti-angiogenic
treatment of malignant tumors.